Last edition
News about
Dalriada Drug Discovery and Topos Bio collaborate to accelerate drug discovery for intrinsically disordered proteins using AI, mass spectrometry and proteomics to improve experimental validation and therapeutic development.
Akums Drugs and Pharmaceuticals introduces DCGI-approved Lasmiditan dispersible tablets, offering faster, patient-friendly migraine relief with improved compliance, especially for patients facing nausea and difficulty swallowing during acute attacks.
NIPER Raebareli Signs MoU with Roche Pharma India to Boost Pharma Education and Research
NIPER Raebareli partners with Roche Pharma India to launch regulatory training, industry lectures and AI-driven research initiatives, strengthening academia-industry collaboration in India’s pharmaceutical sector.
A National Institutes of Health-backed study shows weekly injectable buprenorphine improves opioid abstinence and reduces serious risks compared to sublingual treatment in pregnant women with opioid use disorder.
FTC Tracks Pharma Strategies as Patent Cliff Approaches
The US Federal Trade Commission (FTC) is keeping a close watch on how pharmaceutical companies respond as several blockbuster drugs approach the end of their patent life. The regulator is particularly concerned about practices that could delay the entry of lower-cost generic medicines.
BioVersys AG receives US Food and Drug Administration nod to include US patients in Phase III BV100 trial targeting drug-resistant pneumonia, marking progress in combating deadly hospital infections globally.
Lupin and Zydus Partner to Co-Market Semaglutide Injection in India
Lupin has secured semi-exclusive rights to co-market Zydus’ Semaglutide injection in India under the brands Semanext and Livarise, while Zydus will continue marketing it under the brand names SEMAGLYNTM, MASHEMATM and ALTERMETM.
Dr Jitendra Singh Lays Foundation for INR 600 Crore Orchid Pharma Project in J&K
Dr Jitendra Singh laid the foundation for an INR 600 crore multinational pharma manufacturing facility in Kathua, highlighting the region’s rising industrial potential and its role in strengthening India’s pharma exports and economic growth.
CDSCO Approves AstraZeneca Pharma India's Durvalumab for uHCC Treatment
AstraZeneca Pharma India has received CDSCO approval for durvalumab to treat unresectable hepatocellular carcinoma (uHCC), a major global health concern as HCC ranks among the most common and deadliest cancers worldwide.
Agilisium Invests INR 50 Crore to Accelerate AI Adoption in Life Sciences
Agilisium’s new forward deployment Artificial Intelligence (AI) model embeds specialised experts within life sciences organisations, enabling faster and practical adoption of AI by bridging the gap between innovation and real-world execution.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy